Incorrect preparation of injectable peptides risks overdose, underdose, microbial contamination, injection-site infection, and anaphylaxis
(NEJM, 2023) showed approximately 24% mean weight reduction with Retatrutide at 12 mg at 48 weeks, while Semaglutide demonstrated approximately 15% at 2.4 mg weekly in the STEP trials again, these are cross-trial figures drawn from studies with different designs and populations, and should be treated as indirect
Below is a framework for clinical assessment
Potential risks and side effects of using Semaglutide in the treatment of PCOS The safety profile of semaglutide in the context of PCOS needs to be thoroughly investigated to ensure its appropriateness for this patient
This omission limits pharmacological context, hinders potency normalization across studies, and constrains the prioritization of peptide leads for translational development [177, 178]
Adverse events There was no statistically significant difference in the incidence of adverse events between treatment groups (Table 2)